RU2005104818A - Азаиндольные ингибиторы киназ - Google Patents

Азаиндольные ингибиторы киназ Download PDF

Info

Publication number: RU2005104818A
Authority: RU; Russia
Prior art keywords: substituted; pyrrolo; yloxy; fluoro; methyl
Prior art date: 2002-07-19

Application number

RU2005104818/04A

Other languages

English (en)

Russian (ru)

Inventor

Раджив БХАЙД (US)

Раджив БХАЙД

Реджин РАИЛ (CA)

Реджин РАИЛ

Карл ТИБОЛТ (CA)

Карл ТИБОЛТ

Александр ЛЕРЕ (CA)

Александр ЛЕРЕ

Original Assignee

Бристол-Маерс Сквибб Компани (Us)

Бристол-Маерс Сквибб Компани

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-19

Filing date

2003-07-18

Publication date

2005-07-20

2003-07-18 Application filed by Бристол-Маерс Сквибб Компани (Us), Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани (Us)

2005-07-20 Publication of RU2005104818A publication Critical patent/RU2005104818A/ru

Links

239000003112 inhibitor Substances 0.000 title claims 3
150000001875 compounds Chemical class 0.000 claims 15
239000001257 hydrogen Substances 0.000 claims 12
229910052739 hydrogen Inorganic materials 0.000 claims 12
238000000034 method Methods 0.000 claims 11
241000124008 Mammalia Species 0.000 claims 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
125000001072 heteroaryl group Chemical group 0.000 claims 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
125000000217 alkyl group Chemical group 0.000 claims 6
229910052760 oxygen Inorganic materials 0.000 claims 6
229910052736 halogen Inorganic materials 0.000 claims 5
150000002367 halogens Chemical class 0.000 claims 5
150000002431 hydrogen Chemical class 0.000 claims 5
229910052757 nitrogen Inorganic materials 0.000 claims 5
239000008194 pharmaceutical composition Substances 0.000 claims 5
125000000547 substituted alkyl group Chemical group 0.000 claims 5
102000009465 Growth Factor Receptors Human genes 0.000 claims 4
108010009202 Growth Factor Receptors Proteins 0.000 claims 4
-1 R 31 Chemical compound 0.000 claims 4
125000003118 aryl group Chemical group 0.000 claims 4
125000004093 cyano group Chemical group *C#N 0.000 claims 4
239000003937 drug carrier Substances 0.000 claims 4
125000000623 heterocyclic group Chemical group 0.000 claims 4
230000002401 inhibitory effect Effects 0.000 claims 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
239000000203 mixture Substances 0.000 claims 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
125000003107 substituted aryl group Chemical group 0.000 claims 4
230000001093 anti-cancer Effects 0.000 claims 3
239000002246 antineoplastic agent Substances 0.000 claims 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
239000000460 chlorine Substances 0.000 claims 3
229940127089 cytotoxic agent Drugs 0.000 claims 3
239000002254 cytotoxic agent Substances 0.000 claims 3
231100000599 cytotoxic agent Toxicity 0.000 claims 3
230000000694 effects Effects 0.000 claims 3
239000001301 oxygen Substances 0.000 claims 3
OMJKVIFSWSQTGQ-UHFFFAOYSA-N 6,7-bis(aziridin-1-yl)quinazoline-5,8-dione Chemical compound C1CN1C=1C(=O)C2=NC=NC=C2C(=O)C=1N1CC1 OMJKVIFSWSQTGQ-UHFFFAOYSA-N 0.000 claims 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
102000001253 Protein Kinase Human genes 0.000 claims 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
230000001772 anti-angiogenic effect Effects 0.000 claims 2
125000003710 aryl alkyl group Chemical group 0.000 claims 2
NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 claims 2
201000010099 disease Diseases 0.000 claims 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
125000001153 fluoro group Chemical group F* 0.000 claims 2
125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
108060006633 protein kinase Proteins 0.000 claims 2
229910052717 sulfur Inorganic materials 0.000 claims 2
230000008728 vascular permeability Effects 0.000 claims 2
NTKPIEALXMYDOX-SECBINFHSA-N (2r)-1-[4-[(4-fluoro-1h-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-amine Chemical compound N1=C2NC=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@H](N)C)=C1 NTKPIEALXMYDOX-SECBINFHSA-N 0.000 claims 1
ACPWZRGLIIWDAZ-SECBINFHSA-N (2r)-1-[4-[(4-fluoro-1h-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol Chemical compound N1=C2NC=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@H](O)C)=C1 ACPWZRGLIIWDAZ-SECBINFHSA-N 0.000 claims 1
IEVVBXWLVDGZEQ-SECBINFHSA-N (2r)-1-[4-[(4-fluoro-2-methyl-1h-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-amine Chemical compound N1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@H](N)C)=C1 IEVVBXWLVDGZEQ-SECBINFHSA-N 0.000 claims 1
SDISWWDGAUTYAI-SNVBAGLBSA-N (2r)-1-[4-[(4-fluoro-2-methyl-1h-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol Chemical compound N1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@H](O)C)=C1 SDISWWDGAUTYAI-SNVBAGLBSA-N 0.000 claims 1
ACPWZRGLIIWDAZ-VIFPVBQESA-N (2s)-1-[4-[(4-fluoro-1h-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol Chemical compound N1=C2NC=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@@H](O)C)=C1 ACPWZRGLIIWDAZ-VIFPVBQESA-N 0.000 claims 1
LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 1
LHMXHXQYVFYCCQ-UHFFFAOYSA-N 2-[4-[(4-fluoro-1h-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxyethanamine Chemical compound N1=C2NC=CC2=C(F)C(OC2=NC=NN3C=C(OCCN)C(=C23)C)=C1 LHMXHXQYVFYCCQ-UHFFFAOYSA-N 0.000 claims 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
YYOLIACIIOCPPM-UHFFFAOYSA-N 4-[(4-fluoro-1h-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol Chemical compound N1=C2NC=CC2=C(F)C(OC2=NC=NN3C=C(O)C(=C23)C)=C1 YYOLIACIIOCPPM-UHFFFAOYSA-N 0.000 claims 1
SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical group OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 claims 1
OOQXPATWSOGSAV-UHFFFAOYSA-N 6-(5-methyl-1,3,4-oxadiazol-2-yl)-n-(2-methyl-1h-pyrrolo[2,3-b]pyridin-5-yl)-5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine Chemical compound C=1N2N=CN=C(NC=3C=C4C=C(C)NC4=NC=3)C2=C(C(C)C)C=1C1=NN=C(C)O1 OOQXPATWSOGSAV-UHFFFAOYSA-N 0.000 claims 1
102000012936 Angiostatins Human genes 0.000 claims 1
108010079709 Angiostatins Proteins 0.000 claims 1
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
208000023275 Autoimmune disease Diseases 0.000 claims 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
108010092160 Dactinomycin Proteins 0.000 claims 1
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 claims 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
108010069236 Goserelin Proteins 0.000 claims 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 claims 1
206010061218 Inflammation Diseases 0.000 claims 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
108010000817 Leuprolide Proteins 0.000 claims 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 claims 1
229930012538 Paclitaxel Natural products 0.000 claims 1
229940079156 Proteasome inhibitor Drugs 0.000 claims 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
239000012190 activator Substances 0.000 claims 1
150000003838 adenosines Chemical class 0.000 claims 1
125000003342 alkenyl group Chemical group 0.000 claims 1
125000000304 alkynyl group Chemical group 0.000 claims 1
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims 1
229960001220 amsacrine Drugs 0.000 claims 1
229960002932 anastrozole Drugs 0.000 claims 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
229960000397 bevacizumab Drugs 0.000 claims 1
229960000997 bicalutamide Drugs 0.000 claims 1
BGECDVWSWDRFSP-UHFFFAOYSA-N borazine Chemical compound B1NBNBN1 BGECDVWSWDRFSP-UHFFFAOYSA-N 0.000 claims 1
229960001467 bortezomib Drugs 0.000 claims 1
GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
201000011510 cancer Diseases 0.000 claims 1
229960004562 carboplatin Drugs 0.000 claims 1
229960005395 cetuximab Drugs 0.000 claims 1
229960004630 chlorambucil Drugs 0.000 claims 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
229910052801 chlorine Inorganic materials 0.000 claims 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
229960004316 cisplatin Drugs 0.000 claims 1
229960004397 cyclophosphamide Drugs 0.000 claims 1
229960000978 cyproterone acetate Drugs 0.000 claims 1
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims 1
229960000640 dactinomycin Drugs 0.000 claims 1
229960003668 docetaxel Drugs 0.000 claims 1
229960004679 doxorubicin Drugs 0.000 claims 1
229950004203 droloxifene Drugs 0.000 claims 1
XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 claims 1
XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 claims 1
229960001904 epirubicin Drugs 0.000 claims 1
229930013356 epothilone Natural products 0.000 claims 1
150000003883 epothilone derivatives Chemical class 0.000 claims 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
229960005420 etoposide Drugs 0.000 claims 1
229960000255 exemestane Drugs 0.000 claims 1
229960004039 finasteride Drugs 0.000 claims 1
DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims 1
239000011737 fluorine Substances 0.000 claims 1
229910052731 fluorine Inorganic materials 0.000 claims 1
229960002949 fluorouracil Drugs 0.000 claims 1
229960002074 flutamide Drugs 0.000 claims 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims 1
229960003690 goserelin acetate Drugs 0.000 claims 1
239000003102 growth factor Substances 0.000 claims 1
229940022353 herceptin Drugs 0.000 claims 1
229960000908 idarubicin Drugs 0.000 claims 1
229960001101 ifosfamide Drugs 0.000 claims 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
239000000367 immunologic factor Substances 0.000 claims 1
230000004054 inflammatory process Effects 0.000 claims 1
108010044426 integrins Chemical group 0.000 claims 1
102000006495 integrins Human genes 0.000 claims 1
229960004768 irinotecan Drugs 0.000 claims 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
229940043355 kinase inhibitor Drugs 0.000 claims 1
229960003881 letrozole Drugs 0.000 claims 1
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
229960004961 mechlorethamine Drugs 0.000 claims 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
229960004296 megestrol acetate Drugs 0.000 claims 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 1
229960001924 melphalan Drugs 0.000 claims 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
229960000485 methotrexate Drugs 0.000 claims 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims 1
229960004857 mitomycin Drugs 0.000 claims 1
DNLFTHMQMOVEOZ-UHFFFAOYSA-N n-(4-fluoro-1h-pyrrolo[2,3-b]pyridin-5-yl)-6-(3-methyl-1,2,4-oxadiazol-5-yl)-5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine Chemical compound C=1N2N=CN=C(NC=3C(=C4C=CNC4=NC=3)F)C2=C(C(C)C)C=1C1=NC(C)=NO1 DNLFTHMQMOVEOZ-UHFFFAOYSA-N 0.000 claims 1
CIANRPXQIFFCFG-UHFFFAOYSA-N n-(4-fluoro-1h-pyrrolo[2,3-b]pyridin-5-yl)-6-(5-methyl-1,3,4-oxadiazol-2-yl)-5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine Chemical compound C=1N2N=CN=C(NC=3C(=C4C=CNC4=NC=3)F)C2=C(C(C)C)C=1C1=NN=C(C)O1 CIANRPXQIFFCFG-UHFFFAOYSA-N 0.000 claims 1
IXYUGLGTMIXVHB-UHFFFAOYSA-N n-(4-fluoro-2-methyl-1h-pyrrolo[2,3-b]pyridin-5-yl)-6-(5-methyl-1,3,4-oxadiazol-2-yl)-5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine Chemical compound C=1N2N=CN=C(NC=3C(=C4C=C(C)NC4=NC=3)F)C2=C(C(C)C)C=1C1=NN=C(C)O1 IXYUGLGTMIXVHB-UHFFFAOYSA-N 0.000 claims 1
BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 claims 1
229960002653 nilutamide Drugs 0.000 claims 1
XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims 1
229960001592 paclitaxel Drugs 0.000 claims 1
239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
229960003171 plicamycin Drugs 0.000 claims 1
229940002612 prodrug Drugs 0.000 claims 1
239000000651 prodrug Substances 0.000 claims 1
230000002062 proliferating effect Effects 0.000 claims 1
239000003207 proteasome inhibitor Substances 0.000 claims 1
229960004622 raloxifene Drugs 0.000 claims 1
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 1
102000005962 receptors Human genes 0.000 claims 1
108020003175 receptors Proteins 0.000 claims 1
229960003522 roquinimex Drugs 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
230000019491 signal transduction Effects 0.000 claims 1
239000012453 solvate Substances 0.000 claims 1
125000005017 substituted alkenyl group Chemical group 0.000 claims 1
125000004426 substituted alkynyl group Chemical group 0.000 claims 1
229960001603 tamoxifen Drugs 0.000 claims 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
229960001278 teniposide Drugs 0.000 claims 1
229960001196 thiotepa Drugs 0.000 claims 1
229960000303 topotecan Drugs 0.000 claims 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
229960005026 toremifene Drugs 0.000 claims 1
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
229960005356 urokinase Drugs 0.000 claims 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
229960004528 vincristine Drugs 0.000 claims 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Biotechnology (AREA)
Emergency Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Psychology (AREA)

RU2005104818/04A 2002-07-19 2003-07-18 Азаиндольные ингибиторы киназ RU2005104818A (ru)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US39725602P	2002-07-19	2002-07-19
US60/397256		2002-07-19
US44721303P	2003-02-13	2003-02-13
US60/447213		2003-02-13

Publications (1)

Publication Number	Publication Date
RU2005104818A true RU2005104818A (ru)	2005-07-20

Family

ID=30773005

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
RU2005104818/04A RU2005104818A (ru)	2002-07-19	2003-07-18	Азаиндольные ингибиторы киназ
RU2005104422/04A RU2331642C2 (ru)	2002-07-19	2003-07-18	Новые ингибиторы киназ

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
RU2005104422/04A RU2331642C2 (ru)	2002-07-19	2003-07-18	Новые ингибиторы киназ

Country Status (32)

Country	Link
US (6)	US6969717B2 (2)
EP (3)	EP1534290B1 (2)
JP (2)	JP4381978B2 (2)
KR (1)	KR100901939B1 (2)
CN (3)	CN101880283B (2)
AR (1)	AR040500A1 (2)
AT (2)	ATE505471T1 (2)
AU (2)	AU2003254088B2 (2)
BR (2)	BRPI0312940B1 (2)
CA (2)	CA2492665A1 (2)
CO (1)	CO5680407A2 (2)
CY (1)	CY1112628T1 (2)
DE (1)	DE60336732D1 (2)
DK (1)	DK1534290T3 (2)
ES (1)	ES2377963T3 (2)
GE (2)	GEP20074213B (2)
HR (2)	HRP20050058A2 (2)
IL (3)	IL166129A0 (2)
IS (2)	IS2880B (2)
MX (2)	MXPA05000715A (2)
MY (1)	MY134848A (2)
NO (2)	NO330132B1 (2)
NZ (1)	NZ537523A (2)
PE (1)	PE20040680A1 (2)
PL (2)	PL375352A1 (2)
PT (1)	PT1534290E (2)
RS (2)	RS20050041A (2)
RU (2)	RU2005104818A (2)
SI (1)	SI1534290T1 (2)
TW (1)	TWI329112B (2)
UA (1)	UA82846C2 (2)
WO (2)	WO2004009601A1 (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2404765C2 (ru) *	2005-08-26	2010-11-27	Антисома Рисерч Лимитед	Комбинации (составы), включающие dmxaa для лечения рака
CN116813526A (zh) *	2023-05-22	2023-09-29	四川省医学科学院·四川省人民医院	异吲哚啉酮类化合物、其制备方法及其应用

Families Citing this family (221)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2273083C (en) *	1996-12-03	2012-09-18	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP0881669B1 (en) *	1997-05-30	2005-12-14	STMicroelectronics S.r.l.	Manufacturing process of a germanium implanted heterojunction bipolar transistor
US20020058286A1 (en) *	1999-02-24	2002-05-16	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto and analogues thereof
US6982265B1 (en) *	1999-05-21	2006-01-03	Bristol Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
US6670357B2 (en) *	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) *	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) *	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
PT1497019E (pt)	2002-04-23	2015-09-10	Bristol Myers Squibb Co	Compostos de pirrolotriazina anilina úteis como inibidores de quinase
TW200306841A (en)	2002-04-23	2003-12-01	Bristol Myers Squibb Co	Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
TW200401638A (en) *	2002-06-20	2004-02-01	Bristol Myers Squibb Co	Heterocyclic inhibitors of kinases
TWI329112B (en) *	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (en) *	2002-08-23	2010-05-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
TW200420565A (en)	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
JP2006516653A (ja)	2003-02-05	2006-07-06	ブリストル−マイヤーズ　スクイブ　カンパニー	キナーゼ阻害剤ピロロトリアジンの製造方法
TWI476206B (zh)	2003-07-18	2015-03-11	Amgen Inc	對肝細胞生長因子具專一性之結合劑
US7102001B2 (en)	2003-12-12	2006-09-05	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine
US20060014741A1 (en) *	2003-12-12	2006-01-19	Dimarco John D	Synthetic process, and crystalline forms of a pyrrolotriazine compound
MY145634A (en) *	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
US7064203B2 (en)	2003-12-29	2006-06-20	Bristol Myers Squibb Company	Di-substituted pyrrolotriazine compounds
US7459562B2 (en) *	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) *	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
US7102002B2 (en) *	2004-06-16	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7498342B2 (en)	2004-06-17	2009-03-03	Plexxikon, Inc.	Compounds modulating c-kit activity
US7173031B2 (en) *	2004-06-28	2007-02-06	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7432373B2 (en) *	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
CN1993130B (zh) *	2004-06-28	2010-06-23	布里斯托尔-迈尔斯斯奎布公司	用于制备稠合杂环激酶抑制剂的方法和中间体
US7439246B2 (en) *	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
US7253167B2 (en) *	2004-06-30	2007-08-07	Bristol-Myers Squibb Company	Tricyclic-heteroaryl compounds useful as kinase inhibitors
TW200600513A (en)	2004-06-30	2006-01-01	Bristol Myers Squibb Co	A method for preparing pyrrolotriazine compounds
US7102003B2 (en) *	2004-07-01	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
SE0401790D0 (sv) *	2004-07-07	2004-07-07	Forskarpatent I Syd Ab	Tamoxifen response in pre- and postmenopausal breast cancer patients
US7504521B2 (en) *	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds
TW200618803A (en)	2004-08-12	2006-06-16	Bristol Myers Squibb Co	Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US7151176B2 (en)	2004-10-21	2006-12-19	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
JP2008521900A (ja)	2004-11-30	2008-06-26	アムジエン・インコーポレーテツド	キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
DE102004060659A1 (de)	2004-12-15	2006-07-06	Lanxess Deutschland Gmbh	Neue substituierte 1H-Pyrrolo[2,3-b]pyridine und deren Herstellung
US7534882B2 (en)	2005-04-06	2009-05-19	Bristol-Myers Squibb Company	Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles
US20060257400A1 (en) *	2005-05-13	2006-11-16	Bristol-Myers Squibb Company	Combination therapy
US7846941B2 (en)	2005-05-17	2010-12-07	Plexxikon, Inc.	Compounds modulating c-kit and c-fms activity and uses therefor
WO2006130657A2 (en) *	2005-05-31	2006-12-07	Bristol-Myers Squibb Company	Stereoselective reduction process for the preparation of pyrrolotriazine compounds
US20060288309A1 (en) *	2005-06-16	2006-12-21	Cross Charles W Jr	Displaying available menu choices in a multimodal browser
UA95244C2 (ru)	2005-06-22	2011-07-25	Плексикон, Инк.	Соединения и способ модулирования активности киназ, и показания для их применения
US7402582B2 (en) *	2005-07-01	2008-07-22	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7442700B2 (en) *	2005-07-01	2008-10-28	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7405213B2 (en) *	2005-07-01	2008-07-29	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
ATE543914T1 (de)	2005-09-01	2012-02-15	Bristol Myers Squibb Co	Biomarker und verfahren zur bestimmung der empfindlichkeit gegen vegfr2 modulator.
CN101291934B (zh) *	2005-09-27	2012-06-27	布里斯托尔-迈尔斯·斯奎布公司	[(1R),2S]-2-氨基丙酸2-[4-(4-氟-2-甲基-1H-吲哚-5-基氧基)-5-甲基吡咯并[2,1-f][1,2,4]三嗪-6-基氧基]-1-甲基乙基酯的晶型
US7547782B2 (en) *	2005-09-30	2009-06-16	Bristol-Myers Squibb Company	Met kinase inhibitors
US7514435B2 (en) *	2005-11-18	2009-04-07	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
PE20070855A1 (es)	2005-12-02	2007-10-14	Bayer Pharmaceuticals Corp	Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
WO2007064931A2 (en)	2005-12-02	2007-06-07	Bayer Healthcare Llc	Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
US20080108664A1 (en)	2005-12-23	2008-05-08	Liu Belle B	Solid-state form of AMG 706 and pharmaceutical compositions thereof
AR059066A1 (es)	2006-01-27	2008-03-12	Amgen Inc	Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
JP2009526050A (ja)	2006-02-10	2009-07-16	アムジエン・インコーポレーテツド	Ａｍｇ７０６の水和物形態
US8063208B2 (en)	2006-02-16	2011-11-22	Bristol-Myers Squibb Company	Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
KR20080107408A (ko)	2006-03-07	2008-12-10	브리스톨-마이어스 스큅 컴퍼니	키나제 억제제로서 유용한 피롤로트리아진 아닐린 전구약물화합물
CA2650059A1 (en) *	2006-04-21	2007-11-01	Bristol-Myers Squibb Company	Process for the preparation of [(1r), 2s]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester
WO2008005469A2 (en)	2006-06-30	2008-01-10	Schering Corporation	Igfbp2 biomarker
HRP20140688T1 (hr)	2006-07-07	2014-10-24	Bristol-Myers Squibb Company	Inhibitori piroltriazin kinaze
PE20080403A1 (es)	2006-07-14	2008-04-25	Amgen Inc	Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en)	2006-07-14	2012-07-10	Amgen Inc.	Fused heterocyclic derivatives and methods of use
US7531539B2 (en) *	2006-08-09	2009-05-12	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
WO2008021859A1 (en) *	2006-08-09	2008-02-21	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
CL2007003158A1 (es) *	2006-11-02	2008-05-16	Astrazeneca Ab	Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
AU2007338792B2 (en)	2006-12-20	2012-05-31	Amgen Inc.	Substituted heterocycles and methods of use
JP2010514695A (ja)	2006-12-21	2010-05-06	プレキシコン，インコーポレーテッド	キナーゼ調節のための化合物および方法およびそのための適応症
WO2008079909A1 (en) *	2006-12-21	2008-07-03	Plexxikon, Inc.	Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (es)	2006-12-21	2012-08-24	Plexxikon Inc	Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
US7851500B2 (en)	2007-01-05	2010-12-14	Bristol-Myers Squibb Company	Aminopyrazole kinase inhibitors
AU2008205252B2 (en)	2007-01-09	2013-02-21	Amgen Inc.	Bis-aryl amide derivatives useful for the treatment of cancer
EP2115130B1 (en)	2007-02-08	2011-08-03	Codexis, Inc.	Ketoreductases and uses thereof
MX2009008531A (es)	2007-02-16	2009-08-26	Amgen Inc	Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
WO2008127526A2 (en) *	2007-03-12	2008-10-23	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
US20100234381A1 (en)	2007-04-13	2010-09-16	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
EP2134716A1 (en) *	2007-04-18	2009-12-23	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
TW200902019A (en) *	2007-04-26	2009-01-16	Ono Pharmaceutical Co	Dicyclic heterocyclic compound
WO2009012283A1 (en)	2007-07-17	2009-01-22	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
PL2188313T3 (pl)	2007-08-21	2018-04-30	Amgen, Inc.	Białka wiążące ludzki antygen c-fms
JP2011500086A (ja)	2007-10-22	2011-01-06	シェーリングコーポレイション	完全ヒト抗ｖｅｇｆ抗体および使用方法
US20110086850A1 (en) *	2008-04-11	2011-04-14	Board Of Regents, The University Of Texas System	Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy
CL2009001152A1 (es) *	2008-05-13	2009-10-16	Array Biopharma Inc	Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
ES2539620T3 (es)	2008-12-19	2015-07-02	Cephalon, Inc.	Pirrolotriazina como inhibidor de ALK y de JAK2
WO2010099139A2 (en)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Combination anti-cancer therapy
WO2010099364A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
MY172424A (en)	2009-04-03	2019-11-25	Hoffmann La Roche	Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
US8329724B2 (en)	2009-08-03	2012-12-11	Hoffmann-La Roche Inc.	Process for the manufacture of pharmaceutically active compounds
US20120301463A1 (en)	2009-09-30	2012-11-29	President And Fellows Of Harvard College	Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
WO2011044019A1 (en) *	2009-10-05	2011-04-14	Bristol-Myers Squibb Company	(R)-1-(4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY)PROPAN-2-OL METABOLITES
CN106220623A (zh)	2009-11-06	2016-12-14	普莱希科公司	用于激酶调节的化合物和方法及其适应症
WO2011075620A1 (en)	2009-12-18	2011-06-23	Novartis Ag	Method for treating haematological cancers
WO2011090738A2 (en) *	2009-12-29	2011-07-28	Dana-Farber Cancer Institute, Inc.	Type ii raf kinase inhibitors
WO2011097331A1 (en) *	2010-02-03	2011-08-11	Bristol-Myers Squibb Company	Crystalline forms of (s)-1-(4-(5-cyclopropyl-1h-pyrazol-3- ylamino)pyrrolo [1,2-f] [1,2,4] triazin-2-yl)-n-(6-fluoropyridin- 3-yl)-2-methylpyrrolidine-2-carboxamide
JP5093527B2 (ja) *	2010-02-10	2012-12-12	日本電気株式会社	複合光導波路、波長可変フィルタ、波長可変レーザ、および光集積回路
WO2011161217A2 (en)	2010-06-23	2011-12-29	Palacký University in Olomouc	Targeting of vegfr2
WO2012006550A2 (en) *	2010-07-09	2012-01-12	Obetech Llc	Methods and compositions for treatment of lipogenic virus related conditions
US8338771B2 (en) *	2010-11-05	2012-12-25	Green Plus Co., Ltd.	Apparatus for tracking and condensing sunlight of sliding type
US9624213B2 (en)	2011-02-07	2017-04-18	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es)	2011-02-21	2013-09-18	Plexxikon Inc	Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
EP2937349B1 (en)	2011-03-23	2016-12-28	Amgen Inc.	Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2012149014A1 (en)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US8921533B2 (en)	2011-07-25	2014-12-30	Chromatin Technologies	Glycosylated valproic acid analogs and uses thereof
WO2013025939A2 (en)	2011-08-16	2013-02-21	Indiana University Research And Technology Corporation	Compounds and methods for treating cancer by inhibiting the urokinase receptor
US9382239B2 (en)	2011-11-17	2016-07-05	Dana-Farber Cancer Institute, Inc.	Inhibitors of c-Jun-N-terminal kinase (JNK)
AR090263A1 (es)	2012-03-08	2014-10-29	Hoffmann La Roche	Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
US9724352B2 (en)	2012-05-31	2017-08-08	Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences	Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN103450204B (zh)	2012-05-31	2016-08-17	中国科学院上海药物研究所	吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
US9150570B2 (en)	2012-05-31	2015-10-06	Plexxikon Inc.	Synthesis of heterocyclic compounds
CN102675323B (zh) *	2012-06-01	2014-04-09	南京药石药物研发有限公司	吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途
EP2890696A1 (en)	2012-08-29	2015-07-08	Amgen, Inc.	Quinazolinone compounds and derivatives thereof
CN103664957A (zh) *	2012-09-25	2014-03-26	杨子娇	一类治疗房角狭窄的化合物及其用途
EP2909194A1 (en)	2012-10-18	2015-08-26	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en)	2012-10-19	2020-08-25	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en)	2012-10-19	2014-04-24	Dana-Farber Cancer Institute, Inc.	Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
FR3000494B1 (fr) *	2012-12-28	2015-08-21	Oribase Pharma	Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases
US9050345B2 (en)	2013-03-11	2015-06-09	Bristol-Myers Squibb Company	Pyrrolotriazines as potassium ion channel inhibitors
MX367772B (es)	2013-04-04	2019-09-05	Janssen Pharmaceutica Nv	Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk.
EP3670496A3 (en) *	2013-10-17	2020-09-30	Shionogi&Co., Ltd.	Acc2 inhibitors
EP3057956B1 (en)	2013-10-18	2021-05-05	Dana-Farber Cancer Institute, Inc.	Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015058126A1 (en)	2013-10-18	2015-04-23	Syros Pharmaceuticals, Inc.	Heteroaromatic compounds useful for the treatment of prolferative diseases
CN104725381B (zh) *	2013-12-19	2018-04-10	南京圣和药业股份有限公司	生长因子受体抑制剂及其应用
US9862688B2 (en)	2014-04-23	2018-01-09	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
US9388239B2 (en)	2014-05-01	2016-07-12	Consejo Nacional De Investigation Cientifica	Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
JP6854762B2 (ja)	2014-12-23	2021-04-07	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
HK1247955A1 (zh)	2015-01-08	2018-10-05	小利兰.斯坦福大学托管委员会	提供骨、骨髓及软骨的诱导的因子和细胞
USRE50776E1 (en)	2015-03-27	2026-02-03	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
WO2016201370A1 (en)	2015-06-12	2016-12-15	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
AU2016319125B2 (en)	2015-09-09	2021-04-08	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
ES2969565T3 (es)	2015-09-30	2024-12-13	Max Planck Ges Zur Foerderung Derwissenschaften E V	Derivados heteroarílicos como inhibidores de la sepiapterina reductasa
EP3424505A4 (en)	2016-03-04	2019-10-16	Taiho Pharmaceutical Co., Ltd.	PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en)	2016-03-04	2024-01-30	Taiho Pharmaceuticals Co., Ltd.	Preparation and composition for treatment of malignant tumors
US10577382B2 (en) *	2016-04-28	2020-03-03	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound
AU2017362350B2 (en)	2016-11-18	2021-12-23	Cystic Fibrosis Foundation	Pyrrolopyrimidines as CFTR potentiators
US10131670B2 (en) *	2016-12-16	2018-11-20	Cystic Fibrosis Foundation Therapeutics, Inc.	Bicyclic heteroaryl derivatives as CFTR potentiators
CN110366550A (zh)	2016-12-22	2019-10-22	美国安进公司	作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
US11130761B2 (en) *	2016-12-29	2021-09-28	Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.	Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors
AU2018273356B2 (en)	2017-05-22	2021-09-16	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
AU2018329920B2 (en)	2017-09-08	2022-12-01	Amgen Inc.	Inhibitors of KRAS G12C and methods of using the same
JP6918204B2 (ja)	2018-03-19	2021-08-11	大鵬薬品工業株式会社	アルキル硫酸ナトリウムを含む医薬組成物
EP3788053B1 (en)	2018-05-04	2024-07-10	Amgen Inc.	Kras g12c inhibitors and methods of using the same
CA3098574A1 (en)	2018-05-04	2019-11-07	Amgen Inc.	Kras g12c inhibitors and methods of using the same
MA52564A (fr)	2018-05-10	2021-03-17	Amgen Inc	Inhibiteurs de kras g12c pour le traitement du cancer
US11096939B2 (en)	2018-06-01	2021-08-24	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
MX2020012204A (es)	2018-06-11	2021-03-31	Amgen Inc	Inhibidores de kras g12c para tratar el cáncer.
US11285156B2 (en)	2018-06-12	2022-03-29	Amgen Inc.	Substituted piperazines as KRAS G12C inhibitors
EP3810132A4 (en)	2018-06-25	2022-06-22	Dana-Farber Cancer Institute, Inc.	TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
JP7516029B2 (ja)	2018-11-16	2024-07-16	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
AU2019384118B2 (en)	2018-11-19	2025-06-12	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
AU2019401495B2 (en)	2018-12-20	2025-06-26	Amgen Inc.	Heteroaryl amides useful as KIF18A inhibitors
MA54543A (fr)	2018-12-20	2022-03-30	Amgen Inc	Inhibiteurs de kif18a
JP7686559B2 (ja)	2018-12-20	2025-06-02	アムジエン・インコーポレーテツド	Ｋｉｆ１８ａ阻害剤
JP2022513967A (ja)	2018-12-20	2022-02-09	アムジエン・インコーポレーテツド	Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
US20220040324A1 (en)	2018-12-21	2022-02-10	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugate and kinase inhibitor
US12281126B2 (en)	2018-12-28	2025-04-22	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 and uses thereof
MX2021010323A (es)	2019-03-01	2021-12-10	Revolution Medicines Inc	Compuestos bicíclicos de heterociclilo y usos de este.
MX2021010319A (es)	2019-03-01	2021-12-10	Revolution Medicines Inc	Compuestos biciclicos de heteroarilo y usos de estos.
WO2020231990A1 (en)	2019-05-13	2020-11-19	Relay Therapeutics, Inc.	Fgfr inhibitors and methods of use thereof
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
WO2020236947A1 (en)	2019-05-21	2020-11-26	Amgen Inc.	Solid state forms
EP4007753B1 (en)	2019-08-02	2025-09-24	Amgen Inc.	Kif18a inhibitors
EP4007638A1 (en)	2019-08-02	2022-06-08	Amgen Inc.	Pyridine derivatives as kif18a inhibitors
EP4007756B1 (en)	2019-08-02	2025-12-24	Amgen Inc.	Kif18a inhibitors
EP4007752B1 (en)	2019-08-02	2025-09-24	Amgen Inc.	Kif18a inhibitors
EP4048671B1 (en)	2019-10-24	2026-03-18	Amgen Inc.	Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
IL322454A (en)	2019-11-04	2025-09-01	Revolution Medicines Inc	ras inhibitors
TW202132316A (zh)	2019-11-04	2021-09-01	美商銳新醫藥公司	Ｒａｓ抑制劑
AU2020377925A1 (en)	2019-11-04	2022-05-05	Revolution Medicines, Inc.	Ras inhibitors
CA3156359A1 (en)	2019-11-08	2021-05-14	Adrian Liam Gill	Bicyclic heteroaryl compounds and uses thereof
WO2021094209A1 (en)	2019-11-12	2021-05-20	Bayer Aktiengesellschaft	Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
JP7837865B2 (ja)	2019-11-14	2026-03-31	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の改良合成法
JP2023501528A (ja)	2019-11-14	2023-01-18	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の改善された合成
FI4063364T3 (fi) *	2019-11-18	2024-11-19	Jumbo Drug Bank Co Ltd	Mnk-inhibiittoreina toimivat pyrrolotriatsiiniyhdisteet
EP4065231A1 (en)	2019-11-27	2022-10-05	Revolution Medicines, Inc.	Covalent ras inhibitors and uses thereof
WO2021142026A1 (en)	2020-01-07	2021-07-15	Revolution Medicines, Inc.	Shp2 inhibitor dosing and methods of treating cancer
IL299131A (en)	2020-06-18	2023-02-01	Revolution Medicines Inc	Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
US20250195521A1 (en)	2020-09-03	2025-06-19	Revolution Medicines, Inc.	Use of sos1 inhibitors to treat malignancies with shp2 mutations
CA3194067A1 (en)	2020-09-15	2022-03-24	Revolution Medicines, Inc.	Ras inhibitors
JP7849366B2 (ja)	2020-12-22	2026-04-21	キル・レガー・セラピューティクス・インコーポレーテッド	Ｓｏｓ１阻害剤およびその使用
TW202309052A (zh)	2021-05-05	2023-03-01	美商銳新醫藥公司	Ｒａｓ抑制劑
KR20240017811A (ko)	2021-05-05	2024-02-08	레볼루션 메디슨즈, 인크.	암의 치료를 위한 ras 억제제
JP2024516450A (ja)	2021-05-05	2024-04-15	レボリューションメディシンズインコーポレイテッド	共有結合性ｒａｓ阻害剤及びその使用
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
AU2022379973A1 (en)	2021-11-08	2024-06-27	Progentos Therapeutics, Inc.	Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
CN119212994A (zh)	2021-12-17	2024-12-27	建新公司	作为shp2抑制剂的吡唑并吡嗪化合物
EP4227307A1 (en)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
KR20240156373A (ko)	2022-03-07	2024-10-29	암젠 인크	4-메틸-2-프로판-2-일-피리딘-3-카르보니트릴의 제조 방법
JP2025510572A (ja)	2022-03-08	2025-04-15	レボリューションメディシンズインコーポレイテッド	免疫不応性肺癌を治療するための方法
IL315733A (en) *	2022-04-08	2024-11-01	SHY Therapeutics LLC	Compounds that Interact with RAS Superfamily Proteins for the Treatment of Cancer, Inflammatory, Basoplastic, and Fibrotic Diseases
CN119255825A (zh)	2022-05-24	2025-01-03	第一三共株式会社	抗-cdh6抗体-药物缀合物的剂量方案
WO2023240263A1 (en)	2022-06-10	2023-12-14	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
AU2023358792A1 (en)	2022-10-14	2025-04-17	Black Diamond Therapeutics, Inc.	Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024112656A1 (en) *	2022-11-21	2024-05-30	The Board Of Trustees Of The Leland Stanford Junior University	Use of a tyrosine kinase inhibitor for the treatment of hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension
AU2024241633A1 (en)	2023-03-30	2025-11-06	Revolution Medicines, Inc.	Compositions for inducing ras gtp hydrolysis and uses thereof
CR20250420A (es)	2023-04-07	2025-11-20	Revolution Medicines Inc	Inhibidores macrocíclicos de ras
AR132338A1 (es)	2023-04-07	2025-06-18	Revolution Medicines Inc	Inhibidores de ras
CN121100123A (zh)	2023-04-14	2025-12-09	锐新医药公司	Ras抑制剂的结晶形式
CN121464140A (zh)	2023-04-14	2026-02-03	锐新医药公司	Ras抑制剂的结晶形式、含有其的组合物及其使用方法
TW202508595A (zh)	2023-05-04	2025-03-01	美商銳新醫藥公司	用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
AU2024360599A1 (en) *	2023-10-10	2026-04-09	Shy Therapeutics, Llc	Pyrrolo[2,1-f][1,2,4]triazine compounds acting against cancers, inflammatory diseases, and fibrotic disease via interaction with ras superfamily proteins
AU2024360465A1 (en)	2023-10-12	2026-04-09	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
TW202542151A (zh)	2023-12-22	2025-11-01	美商銳格醫藥有限公司	Ｓｏｓ１抑制劑及其用途
WO2025171296A1 (en)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Ras inhibitors
TW202547461A (zh)	2024-05-17	2025-12-16	美商銳新醫藥公司	Ｒａｓ抑制劑
WO2025255438A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026050446A1 (en)	2024-08-29	2026-03-05	Revolution Medicines, Inc.	Ras inhibitors
WO2026072904A2 (en)	2024-09-26	2026-04-02	Revolution Medicines, Inc.	Compositions and methods for treating lung cancer
CN121159543A (zh) *	2025-09-19	2025-12-19	合肥综合性国家科学中心大健康研究院	吡咯并[2,1-f][1,2,4]三嗪类化合物及其制备方法和应用、中间体、药物组合物和cGAS激动剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL107041A (en) *	1992-09-25	2000-02-17	Lilly Co Eli	Process for preparing omega(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo-6-¬2,3-d¾pyrimidin-5-YL)alkarylcarboxylic acids and N-(omega-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo¬2,3-d¾pyrimidin-5-YL)alk-aroyl-4-glutamic acids
US6191131B1 (en) *	1997-07-23	2001-02-20	Dupont Pharmaceuticals Company	Azolo triazines and pyrimidines
JP4649046B2 (ja) *	1999-05-21	2011-03-09	ブリストル−マイヤーズスクイブカンパニー	キナーゼのピロロトリアジン阻害剤
US6982265B1 (en) *	1999-05-21	2006-01-03	Bristol Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
US6787545B1 (en) *	1999-08-23	2004-09-07	Shiongi & Co., Ltd.	Pyrrolotriazine derivatives having spla2-inhibitory activities
GB0017256D0 (en) *	2000-07-13	2000-08-30	Merck Sharp & Dohme	Therapeutic agents
WO2002012227A2 (en) *	2000-08-09	2002-02-14	Astrazeneca Ab	Indole, azaindole and indazole derivatives having vegf inhibiting activity
GEP20063915B (en) *	2000-11-17	2006-09-11	Bristol Myers Squibb Co	PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
US6867300B2 (en) *	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en)	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) *	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
TW200306841A (en) *	2002-04-23	2003-12-01	Bristol Myers Squibb Co	Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
PT1497019E (pt) *	2002-04-23	2015-09-10	Bristol Myers Squibb Co	Compostos de pirrolotriazina anilina úteis como inibidores de quinase
TW200400034A (en) *	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TW200407143A (en) *	2002-05-21	2004-05-16	Bristol Myers Squibb Co	Pyrrolotriazinone compounds and their use to treat diseases
TWI329112B (en) *	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
TWI272271B (en) *	2002-07-19	2007-02-01	Bristol Myers Squibb Co	Process for preparing certain pyrrolotriazine compounds
AU2003265349A1 (en)	2002-08-02	2004-02-23	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
TW200420565A (en)	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
JP2006516653A (ja)	2003-02-05	2006-07-06	ブリストル−マイヤーズ　スクイブ　カンパニー	キナーゼ阻害剤ピロロトリアジンの製造方法

2003
- 2003-07-14 TW TW092119165A patent/TWI329112B/zh not_active IP Right Cessation
- 2003-07-17 MY MYPI20032690A patent/MY134848A/en unknown
- 2003-07-18 AU AU2003254088A patent/AU2003254088B2/en not_active Expired
- 2003-07-18 PL PL03375352A patent/PL375352A1/xx not_active Application Discontinuation
- 2003-07-18 BR BRPI0312940-3A patent/BRPI0312940B1/pt active IP Right Grant
- 2003-07-18 US US10/622,593 patent/US6969717B2/en not_active Expired - Lifetime
- 2003-07-18 AR AR20030102587A patent/AR040500A1/es active IP Right Grant
- 2003-07-18 EP EP03765881A patent/EP1534290B1/en not_active Expired - Lifetime
- 2003-07-18 EP EP10180960A patent/EP2280012A3/en not_active Withdrawn
- 2003-07-18 SI SI200332120T patent/SI1534290T1/sl unknown
- 2003-07-18 MX MXPA05000715A patent/MXPA05000715A/es active IP Right Grant
- 2003-07-18 PL PL375389A patent/PL216663B1/pl unknown
- 2003-07-18 CN CN2010101428920A patent/CN101880283B/zh not_active Expired - Lifetime
- 2003-07-18 RS YUP-2005/0041A patent/RS20050041A/sr unknown
- 2003-07-18 WO PCT/US2003/022554 patent/WO2004009601A1/en not_active Ceased
- 2003-07-18 DK DK03765881.2T patent/DK1534290T3/da active
- 2003-07-18 HR HR20050058A patent/HRP20050058A2/hr not_active Application Discontinuation
- 2003-07-18 GE GEAP8643A patent/GEP20074213B/en unknown
- 2003-07-18 RU RU2005104818/04A patent/RU2005104818A/ru not_active Application Discontinuation
- 2003-07-18 DE DE60336732T patent/DE60336732D1/de not_active Expired - Lifetime
- 2003-07-18 GE GEAP8644A patent/GEP20074124B/en unknown
- 2003-07-18 HR HRP20050059A patent/HRP20050059B8/hr not_active IP Right Cessation
- 2003-07-18 JP JP2004523591A patent/JP4381978B2/ja not_active Expired - Fee Related
- 2003-07-18 AT AT03765754T patent/ATE505471T1/de not_active IP Right Cessation
- 2003-07-18 RS YU20050042A patent/RS52325B/sr unknown
- 2003-07-18 AT AT03765881T patent/ATE537843T1/de active
- 2003-07-18 WO PCT/US2003/022826 patent/WO2004009784A2/en not_active Ceased
- 2003-07-18 EP EP03765754A patent/EP1539763B1/en not_active Expired - Lifetime
- 2003-07-18 RU RU2005104422/04A patent/RU2331642C2/ru active
- 2003-07-18 PT PT03765881T patent/PT1534290E/pt unknown
- 2003-07-18 IL IL16612903A patent/IL166129A0/xx active IP Right Grant
- 2003-07-18 JP JP2004523256A patent/JP4361485B2/ja not_active Expired - Lifetime
- 2003-07-18 UA UAA200501515A patent/UA82846C2/uk unknown
- 2003-07-18 ES ES03765881T patent/ES2377963T3/es not_active Expired - Lifetime
- 2003-07-18 KR KR1020087022726A patent/KR100901939B1/ko not_active Expired - Lifetime
- 2003-07-18 BR BRPI0312801-6A patent/BR0312801A/pt unknown
- 2003-07-18 AU AU2003254017A patent/AU2003254017A1/en not_active Abandoned
- 2003-07-18 CN CN038219158A patent/CN1681508B/zh not_active Expired - Lifetime
- 2003-07-18 CA CA002492665A patent/CA2492665A1/en not_active Abandoned
- 2003-07-18 CN CNB038218208A patent/CN1315833C/zh not_active Expired - Fee Related
- 2003-07-18 US US10/623,171 patent/US6869952B2/en not_active Expired - Lifetime
- 2003-07-18 CA CA002492804A patent/CA2492804C/en not_active Expired - Lifetime
- 2003-07-18 NZ NZ537523A patent/NZ537523A/en not_active IP Right Cessation
- 2003-07-18 MX MXPA05000716A patent/MXPA05000716A/es unknown
- 2003-07-21 PE PE2003000721A patent/PE20040680A1/es not_active Application Discontinuation
2005
- 2005-01-03 IL IL166129A patent/IL166129A/en unknown
- 2005-01-06 NO NO20050072A patent/NO330132B1/no not_active IP Right Cessation
- 2005-01-11 IL IL16623205A patent/IL166232A0/xx unknown
- 2005-01-12 IS IS7647A patent/IS2880B/is unknown
- 2005-01-12 IS IS7646A patent/IS7646A/is unknown
- 2005-01-13 US US11/035,248 patent/US7265113B2/en not_active Expired - Lifetime
- 2005-01-19 CO CO05003967A patent/CO5680407A2/es active IP Right Grant
- 2005-01-25 NO NO20050417A patent/NO20050417L/no not_active Application Discontinuation
- 2005-08-29 US US11/214,267 patent/US20060058304A1/en not_active Abandoned
2007
- 2007-08-02 US US11/832,976 patent/US7521450B2/en not_active Expired - Lifetime
2009
- 2009-03-06 US US12/399,429 patent/US7820814B2/en not_active Expired - Lifetime
2012
- 2012-03-14 CY CY20121100271T patent/CY1112628T1/el unknown

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2404765C2 (ru) *	2005-08-26	2010-11-27	Антисома Рисерч Лимитед	Комбинации (составы), включающие dmxaa для лечения рака
CN116813526A (zh) *	2023-05-22	2023-09-29	四川省医学科学院·四川省人民医院	异吲哚啉酮类化合物、其制备方法及其应用

Also Published As

Publication number	Publication date
PL216663B1 (pl)	2014-04-30
BRPI0312940B1 (pt)	2019-07-23
US7820814B2 (en)	2010-10-26
EP1539763A4 (en)	2007-08-01
US20070299075A1 (en)	2007-12-27
AU2003254088B2 (en)	2008-07-17
CN101880283B (zh)	2012-07-18
CO5680407A2 (es)	2006-09-29
ATE505471T1 (de)	2011-04-15
NO20050417L (no)	2005-02-17
US6969717B2 (en)	2005-11-29
US20040072832A1 (en)	2004-04-15
CY1112628T1 (el)	2016-02-10
WO2004009784A3 (en)	2004-04-22
IS7646A (is)	2005-01-12
IS2880B (is)	2014-05-15
RS52325B (sr)	2012-12-31
CA2492804C (en)	2009-06-23
TW200412973A (en)	2004-08-01
CN1681818A (zh)	2005-10-12
CN1315833C (zh)	2007-05-16
BR0312940A (pt)	2005-06-21
JP4361485B2 (ja)	2009-11-11
US7521450B2 (en)	2009-04-21
PL375389A1 (en)	2005-11-28
ES2377963T3 (es)	2012-04-03
AU2003254088A1 (en)	2004-02-09
IL166129A (en)	2015-04-30
EP1534290A2 (en)	2005-06-01
NZ537523A (en)	2007-08-31
HK1072545A1 (en)	2005-09-02
GEP20074124B (en)	2007-06-11
EP1534290A4 (en)	2006-11-29
HRP20050059B8 (hr)	2016-03-25
BR0312801A (pt)	2007-06-26
ATE537843T1 (de)	2012-01-15
DK1534290T3 (da)	2012-04-10
JP2005538990A (ja)	2005-12-22
IL166232A0 (en)	2006-01-15
NO330132B1 (no)	2011-02-21
AR040500A1 (es)	2005-04-06
CN1681508A (zh)	2005-10-12
WO2004009784A2 (en)	2004-01-29
MXPA05000716A (es)	2005-04-08
CN101880283A (zh)	2010-11-10
RS20050041A (sr)	2007-06-04
DE60336732D1 (de)	2011-05-26
HRP20050059A2 (en)	2005-04-30
HRP20050059B1 (hr)	2015-02-27
US20040063707A1 (en)	2004-04-01
TWI329112B (en)	2010-08-21
EP1539763A1 (en)	2005-06-15
WO2004009601A1 (en)	2004-01-29
EP1534290B1 (en)	2011-12-21
IL166129A0 (en)	2006-01-15
US7265113B2 (en)	2007-09-04
PT1534290E (pt)	2012-03-05
GEP20074213B (en)	2007-10-10
MXPA05000715A (es)	2006-02-22
RU2331642C2 (ru)	2008-08-20
EP2280012A2 (en)	2011-02-02
AU2003254017A1 (en)	2004-02-09
JP4381978B2 (ja)	2009-12-09
IS7647A (is)	2005-01-12
KR100901939B1 (ko)	2009-06-10
MY134848A (en)	2007-12-31
CN1681508B (zh)	2010-10-06
EP1539763B1 (en)	2011-04-13
EP2280012A3 (en)	2011-05-18
RU2005104422A (ru)	2005-08-10
CA2492804A1 (en)	2004-01-29
KR20080095906A (ko)	2008-10-29
US20060058304A1 (en)	2006-03-16
NO20050072L (no)	2005-02-03
US20050124621A1 (en)	2005-06-09
US20090170853A1 (en)	2009-07-02
PE20040680A1 (es)	2004-10-08
BRPI0312940B8 (2)	2021-05-25
SI1534290T1 (sl)	2012-05-31
JP2005538989A (ja)	2005-12-22
US6869952B2 (en)	2005-03-22
HRP20050058A2 (en)	2005-08-31
CA2492665A1 (en)	2004-01-29
PL375352A1 (en)	2005-11-28
RS20050042A (sr)	2007-06-04
UA82846C2 (en)	2008-05-26

Legal Events

Date	Code	Title	Description
2006-11-27	FA92	Acknowledgement of application withdrawn (lack of supplementary materials submitted)	Effective date: 20061013

Publication	Publication Date	Title
RU2005104818A (ru)	2005-07-20	Азаиндольные ингибиторы киназ
JP7266630B2 (ja)	2023-04-28	ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
JP7206314B2 (ja)	2023-01-17	Ｊａｋ及びｐｉ３ｋ阻害剤併用によるｂ細胞悪性腫瘍の処置
US9951065B2 (en)	2018-04-24	Benzimidazole and imadazopyridine carboximidamide compounds
CA2520898C (en)	2009-10-20	Non-cross-linking pyrrolo(2,1-c)(1,4)benzodiazepines as potential antitumour agents and process thereof
CA2552107A1 (en)	2005-07-21	Pyrrolotriazine compounds as kinase inhibitors
WO2022187528A1 (en)	2022-09-09	Quinazoline amine derivatives as kras inhibitors
JP2007538092A5 (2)	2008-07-03
WO2017207387A1 (en)	2017-12-07	Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
CA2974853A1 (en)	2016-08-04	4h-pyrrolo[3,2-c]pyridin-4-one derivatives
JP2006504624A5 (2)	2006-04-20
RU2014126750A (ru)	2016-01-27	Ингибиторы тирозинкиназы брутона
CA3115068A1 (en)	2020-04-09	Method for preparing and delivering bisantrene formulations
JP2006512366A5 (2)	2006-09-28
RU98117245A (ru)	2000-10-20	2-(арилфенил)аминоимидазолиновые производные
WO2006044402A1 (en)	2006-04-27	Furazano `3, 4-b ! pyrazynes and their use as anti-tumor agents
US10836747B2 (en)	2020-11-17	Ethane-sulfonate salt of quinoline derivative
WO2025233865A1 (en)	2025-11-13	Enpp1 inhibitors
CN121399105A (zh)	2026-01-23	杂芳族dhodh抑制剂
KR20250096877A (ko)	2025-06-27	치환된 헤테로고리 화합물 유도체 및 그의 약학적 용도
CA3149900A1 (en)	2021-03-11	Rip1 inhibitory compounds and methods for making and using the same

RU2005104818A - Азаиндольные ингибиторы киназ - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (4)

Publications (1)

Family

ID=30773005

Family Applications (2)

Family Applications After (1)

Country Status (32)

Cited By (2)

Families Citing this family (221)

Family Cites Families (20)

Cited By (2)

Also Published As

Similar Documents

Legal Events